A systematic review of the correlation between serum asymmetric dimethylarginine, carotid atherosclerosis and ischaemic stroke

Abstract

Objective: To investigate the correlation between serum asymmetric dimethylarginine (ADMA) and the risk of ischaemic stroke and carotid atherosclerosis in adults. Methods: We systematically searched PubMed, EMBASE, Web of Science and other databases for relevant studies on serum ADMA and ischaemic stroke or carotid atherosclerosis, which were published from December 1980 to December 2019. The quality of the included studies was evaluated according to the Cochrane system evaluation standard. The difference in serum ADMA level between ischaemic stroke and control group was selected as the effect size (standardized mean difference, SMD).The pooled analysis was performed using Review Manager (V.5.3). Results: According to the selection criteria, thirteen studies were included in the meta-analysis after screening. Nine studies compared ADMA levels between the ischaemic stroke group and healthy control group, involving a total of 1315 and 880 subjects in the two groups, respectively. Pooled effect sizes were calculated using the random-effects model due to the high heterogeneity (I 2 = 93%, P < .00001). The level of serum ADMA in patients with ischaemic stroke was significantly higher than that in healthy people (SDM = 0.69, 95% CI [0.32, 1.06], P = .0002). Seven of the thirteen articles compared ADMA levels between the carotid arteriosclerosis group and the healthy control group, with 559 and 330 subjects in the two groups, respectively. The random-effects model was applied due to the high heterogeneity (I 2 = 91%, P < .00001). The level of serum ADMA in patients with carotid arteriosclerosis was significantly higher than that in healthy people (SDM = 1.03, 95% CI [0.49, 1.57], P = .0002). Conclusion:The serum ADMA may be related to ischaemic stroke, and it is a risk factor for carotid atherosclerosis.

The Role of Biomarkers in Atherothrombotic Stroke—A Systematic Review

“…Asymmetric dimethylarginine (ADMA) is a derivate product from the normal protein metabolism, being an endogenous inhibitor of nitric oxide (NO) synthesis in the vascular endothelium [88].…”

“…Several studies have shown that increased ADMA levels are associated with the atherosclerosis process and endothelial dysfunction [88,90].…”

Changes and Correlations of the Intestinal Flora and Liver Metabolite Profiles in Mice With Gallstones

“…Hepatic IR was found to be an independent risk factor for GSD ( Biddinger et al, 2008 ; Chang et al, 2008 ); therefore, we infer that ADMA plays a promoting role in the process of gallstone development. ADMA is an endogenous inhibitor of nitric oxide (NO) synthetase, and endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is a risk factor for atherogenesis ( Qin et al, 2021 ), myocardial infarction ( Mannino et al, 2019 ), and chronic kidney disease ( Shah et al, 2021 ). At the same time, studies have shown that GB hypomotility plays a key role in gallbladder (GB) normal relaxation ( Chen et al, 1997 ; Swartz-Basile et al, 2000 ), while GB hypomotility is also a required factor for gallstone pathogenesis.…”

Association of MMP-9, ADMA, and sCD40L with ischemic stroke and correlations with stroke severity: A case-control study

“…Janes et al [30] showed that ADMA levels are associated with cerebral small vessel disease in asymptomatic patients. A recent review showed that high ADMA levels were associated with carotid atherosclerosis, which is a risk factor for ischemic stroke [31]. Still, some studies suggest that ADMA levels are not associated with stroke [32][33][34].…”